The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
about
Systemic antibiotics for treating diabetic foot infectionsCommunity-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicPhase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsCombinatorial biosynthesis of novel antibiotics related to daptomycinDaptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciCyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteriaNovel formulations for antimicrobial peptidesEfficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trialsSynthetic biology of antimicrobial discoveryBacterial genome engineering and synthetic biology: combating pathogensEfficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysisNew developments in the management of severe skin and deep skin structure infections - focus on tedizolidAcute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.Prevention of vancomycin induced nephrotoxicity: a review of preclinical data.Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports.Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Daptomycin in experimental murine pneumococcal meningitis.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Strain improvement of Streptomyces roseosporus for daptomycin production by rational screening of He-Ne laser and NTG induced mutants and kinetic modeling.Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials.In vitro activity and killing effect of citropin 1.1 against gram-positive pathogens causing skin and soft tissue infections.A potential role for daptomycin in enterococcal infections: what is the evidence?Waves of resistance: Staphylococcus aureus in the antibiotic era.Methicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Safety and efficacy of commonly used antimicrobial agents in the treatment of enterococcal infections: a review.Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patientsSmall molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria.Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort studyClinical experience with daptomycin in Europe: the first 2.5 years.Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.Methicillin-resistant Staphylococcus aureus in HIV-infected patients.
P2860
Q24187313-8330ED9C-B455-42FA-9BA1-F3DEA8CF1C8BQ24614464-CC47B5A1-C61B-44B5-A12B-356F57589801Q24672937-762D7463-AE78-4989-996E-7FDF582AB02FQ24676630-B139471F-B528-4BB7-8A96-3455296ED5FBQ26752922-D93124BF-A3A5-4A23-A70A-5E238D096F47Q26853465-EB533E4F-2870-4AA0-A696-4141E2B8DE27Q26863225-9B7F6FAF-94C6-4427-A23A-8DBB052634F4Q26991771-4F8839A3-FED6-4AB5-A96F-93870641116AQ27000445-47973AAC-E4F1-46D9-B4B6-874D938E493CQ27001264-CF1DA60F-F39C-42BE-B890-22910A3FA9DEQ28066540-FF0B2DB6-DDC4-4FA0-ABF7-A2EC32C74255Q28070326-BE801C0F-41B6-4914-BAF1-8347C3DE3F04Q28083116-DEDBC4AF-1B82-4F6F-94CD-375292D5A6EEQ30251580-7F55470F-0E27-48F4-B924-4A0DAC7979DEQ30569251-404D60C0-8CDC-412B-8E3F-30A6D919290AQ30653432-95A3AB84-A028-4CA7-A607-2A4849849F0FQ33239640-82DE99D1-627D-4F92-8A9F-4ED2408A023AQ33260093-01299CE9-AE4B-4D61-B104-FCFE79263630Q33429168-DA273476-2277-4CBF-900F-B54E66F23599Q33437256-37C4B7E1-E961-4D48-957F-B2194F2A475AQ33438834-5AA28209-5710-4FC5-9B1A-F00A97098281Q33617737-5F66256B-580F-468F-87A0-9C9D4324A7F8Q33657212-CE2F877F-3A3E-4EB1-AA43-970E36EAB380Q33707870-C667C0D3-B7BA-4EA2-A07D-68205F2041FBQ33768851-6BA4180A-8B5B-4A05-A9CE-D86E23E2F235Q33834856-0FB82671-D9AE-4292-B622-0C1F98585B92Q33836677-897BC2A3-B6F5-410A-86BB-8DBC06D05FF8Q33845776-D77F682A-F76C-494F-A57D-46CF5EB095F3Q33854398-F09F8861-35C9-45A8-9E0D-A58C721A50ABQ33970752-5551F073-452E-4D57-822C-71B3D79520C9Q34157657-A627A935-7D95-405D-970A-42786702D777Q34187667-B8839402-D6AD-4B4A-8A57-21542D41BCD8Q34478074-7DE6C303-F424-4785-B10A-0D2BC1D2A547Q34503844-9DB473E3-DB94-4985-81D7-CD60DA116EE2Q34573702-5C9C6A36-F12F-446F-AEC6-2ADA57A505CDQ34582921-1CEF022B-BE3A-42A6-881B-1F098C087521Q34583169-A7CEDC16-F1F1-4959-88E4-9A0960FC32FAQ34681219-97F47453-7CA0-498C-ACE7-93CB0C521682Q34718540-8BC6A842-8F94-4541-8E12-9EE76EE95694Q35026548-ED1EB665-922F-4AC8-B723-405D91D63B77
P2860
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
The safety and efficacy of dap ...... and skin-structure infections.
@ast
The safety and efficacy of dap ...... and skin-structure infections.
@en
The safety and efficacy of dap ...... and skin-structure infections.
@nl
type
label
The safety and efficacy of dap ...... and skin-structure infections.
@ast
The safety and efficacy of dap ...... and skin-structure infections.
@en
The safety and efficacy of dap ...... and skin-structure infections.
@nl
prefLabel
The safety and efficacy of dap ...... and skin-structure infections.
@ast
The safety and efficacy of dap ...... and skin-structure infections.
@en
The safety and efficacy of dap ...... and skin-structure infections.
@nl
P2093
P2860
P356
P1476
The safety and efficacy of dap ...... and skin-structure infections.
@en
P2093
Barry I Eisenstein
Daptomycin 98-01 and 99-01 Investigators
Dennis Maki
Edward Campanaro
Francis P Tally
Robert D Arbeit
P2860
P304
P356
10.1086/420818
P407
P577
2004-05-20T00:00:00Z